**Supplemental material**

Supplemental table 1a. Demographics and baseline characteristics in Group A (patients with uncontrolled bleeding).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | GI  (*n* = 20) | Subdural hemorrhage  (*n* = 6) | Deep intracerebral and subarachnoid hemorrhage  (*n* = 12) | Other bleeds  (*n* = 13) | Total  (*n* = 51) |
| Male, *n* (%) | 12 (60) | 5 (83) | 6 (50) | 9 (69) | 32 (63) |
| Age, years, median (min, max) | 77.0 (60, 93) | 76.5 (70, 83) | 83.0 (48, 88) | 76.0 (52, 87) | 77.0 (48, 93) |
| Creatinine clearance median (min, max), mL/min | 48.65 (18.90, 66.99) | 65.00 (34.50, 111.38) | 51.54 (38.66, 130.35) | 64.79 (15.75, 186.77) | 53.92 (15.75, 186.77) |
| Daily dose of dabigatran, *n* (%) |  |  |  |  |  |
| 110 mg bid | 13 (65.0) | 3 (50.0) | 9 (75.0) | 9 (69.2) | 34 (66.7) |
| 150 mg bid | 6 (30.0) | 3 (50.0) | 2 (16.7) | 3 (23.1) | 14 (27.5) |
| 75 mg bid |  |  | 1 (8.3) |  | 1 (2.0) |
| Other | 1 (5.0) |  |  | 1 (7.7) | 2 (3.9) |
| Dabigatran indication, *n* (%) |  |  |  |  |  |
| Atrial fibrillation | 18 (90.0) | 6 (100.0) | 11 (91.7) | 12 (92.3) | 47 (92.2) |
| VTE |  |  |  | 1 (7.7) | 1 (2.0) |
| Other | 2 (10.0) |  | 1 (8.3) |  | 3 (5.9) |
| Time since last dabigatran intake, *n* (%) |  |  |  |  |  |
| <12 hours | 7 (35.0) | 2 (33.3) | 4 (33.3) | 4 (30.8) | 17 (33.3) |
| ≥12 to <24 hours | 7 (35.0) | 2 (33.3) | 5 (41.7) | 7 (53.8) | 21 (41.2) |
| ≥24 to <48 hours | 5 (25.0) | 2 (33.3) | 3 (25.0) | 2 (15.4) | 12 (23.5) |
| ≥48 hours | 1 (5.0) |  |  |  | 1 (2.0) |
| Baseline dTT, *n* (%) |  |  |  |  |  |
| ≤ULN | 2 (10.0) | 3 (50.0) | 4 (33.3) | 2 (15.4) | 11 (21.6) |
| >ULN | 18 (90.0) | 3 (50.0) | 8 (66.7) | 11 (84.6) | 40 (78.4) |
| Baseline ECT, *n* (%) |  |  |  |  |  |
| ≤ULN |  | 2 (33.3) | 1 (8.3) | 1 (7.7) | 4 (7.8) |
| >ULN | 20 (100) | 4 (66.7) | 11 (91.7) | 12 (92.3) | 47 (92.2) |

bid, twice daily; dTT, diluted thrombin time; ECT, ecarin clotting time; GI, gastrointestinal; SD, standard deviation;   
ULN, upper limit of normal; VTE, venous thromboembolism.

Supplemental table 1b. Demographics and baseline characteristics in Group B (patients undergoing emergency surgery/procedures).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Musculo-skeletal trauma surgery/ procedures  (*n* = 8) | Cardiac and vascular surgery/ procedures  (*n* = 3) | Major therapeutic abdominal surgery/ procedures  (*n* = 10) | Exploratory abdominal surgery/ procedures  (*n* = 4) | Infections of skin and subcutaneous tissues, joint infection (*n* = 6) | Other surgery/ procedures  (*n* = 8) | Total  (*n* = 39) |
| Male, *n* (%) | 4 (50) | 2 (67) | 3 (30) | 2 (50) | 3 (50) | 4 (50) | 18 (46) |
| Age, years, median (min, max) | 83.5 (59, 92) | 70.0 (64, 73) | 74.0 (63, 90) | 87.5 (80, 93) | 75.5 (56, 84) | 77.0 (60, 87) | 76.0 (56, 93) |
| Creatinine clearance median (min, max), mL/min | 79.86 (28.38, 98.35) | 72.79 (67.11, 78.46) | 53.18 (25.21, 126.07) | 22.74 (19.49, 25.99) | 60.63 (43.31, 171.02) | 49.22 (11.50, 131.30) | 60.10 (11.50, 171.02) |
| Daily dose of dabigatran, *n* (%) |  |  |  |  |  |  |  |
| 110 mg bid | 7 (87.5) |  | 6 (60.0) | 4 (100) | 3 (50.0) | 4 (50.0) | 24 (61.5) |
| 150 mg bid | 1 (12.5) | 3 (100) | 4 (40.0) |  | 3 (50.0) | 4 (50.0) | 15 (38.5) |
| 75 mg bid |  |  |  |  |  |  |  |
| Other |  |  |  |  |  |  |  |
| Dabigatran indication, *n* (%) |  |  |  |  |  |  |  |
| Atrial fibrillation | 8 (100) | 3 (100) | 10 (100) | 4 (100) | 6 (100) | 8 (100) | 39 (100) |
| VTE |  |  |  |  |  |  |  |
| Other |  |  |  |  |  |  |  |
| Time since last dabigatran intake, *n* (%) |  |  |  |  |  |  |  |
| <12 hours | 3 (37.5) |  | 3 (30.0) | 3 (75.0) | 3 (50.0) | 3 (37.5) | 15 (38.5) |
| ≥12 to <24 hours | 3 (37.5) | 1 (33.3) | 2 (20.0) | 1 (25.0) | 1 (16.7) | 2 (25.0) | 10 (25.6) |
| ≥24 to <48 hours | 1 (12.5) | 1 (33.3) | 4 (40.0) |  | 2 (33.3) | 2 (25.0) | 10 (25.6) |
| ≥48 hours | 1 (12.5) | 1 (33.3) | 1 (10.0) |  |  | 1 (12.5) | 4 (10.3) |
| Baseline dTT, *n* (%) |  |  |  |  |  |  |  |
| ≤ULN | 2 (25.0) | 2 (66.7) | 3 (30.0) |  | 2 (33.3) | 2 (25.0) | 11 (28.2) |
| >ULN | 6 (75.0) | 1 (33.3) | 7 (70.0) | 4 (100) | 4 (66.6) | 6 (75.0) | 28 (71.8) |
| Baseline ECT, *n* (%)\* |  |  |  |  |  |  |  |
| ≤ULN | 1 (12.5) |  | 2 (20.0) |  |  | 2 (25.0) | 5 (12.8) |
| >ULN | 7 (87.5) | 3 (100) | 8 (80.0) | 3 (75.0) | 6 (100) | 6 (75.0) | 33 (84.6) |

bid, twice daily; dTT, diluted thrombin time; ECT, ecarin clotting time; SD, standard deviation; ULN, upper limit of normal; VTE, venous thromboembolism.

\*Data missing from one patient undergoing exploratory abdominal surgery/procedure.